Moleculin Biotech, Inc. — Q3 2021 Form 10-Q
Business context and period. Clinical-stage pharmaceutical company developing drug candidates for resistant cancers and viral diseases. This unaudited report covers the three and nine months ended September 30, 2021; comparisons are with the corresponding 2020 periods. The company had no revenue and reported no commercial product sales.
Key financial metrics
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $4.1 million | $4.4 million | $11.2 million | $11.0 million |
| General and administrative | $2.0 million | $1.7 million | $6.4 million | $5.1 million |
| Operating loss | $6.2 million | $6.2 million | $17.8 million | $16.2 million |
| Net loss | $4.4 million | $3.4 million | $13.1 million | $14.7 million |
| Cash used in operating activities | Not provided for quarter | Not provided for quarter | $14.7 million | $14.6 million |
- At September 30, 2021, cash and cash equivalents were $75.2 million, versus $15.2 million at December 31, 2020; current assets were $77.1 million and current liabilities $3.7 million.
- Total liabilities were $7.4 million, including a $3.7 million long-term warrant liability and lease obligations. The filing reports no conventional borrowings.
- Stockholders’ equity was $81.3 million. Common shares outstanding increased to 28.6 million from 11.5 million at year-end 2020, primarily following equity offerings.
- Operating expenses exceeded revenue, so operating and profit margins are not meaningful. The company reported an accumulated deficit of $70.0 million.
Material changes versus prior periods
- Q3 operating loss was essentially unchanged year over year, while net loss increased by about $1.0 million. The fair-value warrant gain declined to $1.7 million from $2.7 million, partly offsetting the operating loss in both periods.
- For the first nine months, operating loss increased by about $1.5 million, while net loss improved by about $1.6 million. The $4.4 million warrant revaluation gain in 2021, compared with $1.5 million in 2020, materially affected the comparison; it is a noncash accounting item.
- Nine-month R&D expense rose modestly, attributed mainly to increased clinical-trial activity and drug-product manufacturing. G&A increased $1.3 million, primarily due to consulting and advisory fees and corporate insurance.
- Financing provided $74.7 million in cash during the first nine months, primarily from the February 2021 public offering; operating activities used $14.7 million. Cash increased by $60.0 million overall.
Outlook, management commentary, and risks
- Management stated that September 30 cash was expected to fund projected operating requirements into 2024, including a forecast increase in R&D spending. The company expects continued operating losses and negative operating cash flow for several years; projections depend on clinical and preclinical spending and could change.
- Clinical focus includes Annamycin trials in AML and soft-tissue sarcoma lung metastases, externally sponsored WP1066 brain-tumor studies, and planned WP1122 development. UK authorization for a Phase 1a WP1122 trial was received in October 2021. The company also planned a U.S. IND filing for WP1122 and further Annamycin studies; timing and execution remain uncertain.
- Management reported preliminary Annamycin soft-tissue sarcoma data from the first two cohorts as 80% clinical activity (stable disease or better), with no dose-limiting toxicities reported to date. These are early, limited clinical observations and do not establish efficacy.
- COVID-19 had slowed trial recruitment and restricted monitoring access at some Polish clinics. Worldwide supply-chain delays began affecting certain shipments in Q3; the company relies on third parties for manufacturing and has no manufacturing facilities. Management said operations had not been materially affected to date but cautioned that conditions could worsen.
- Other key risks include clinical and regulatory uncertainty, patient recruitment, dependence on third-party manufacturers and collaborators, maintaining intellectual-property licenses, and the possibility that additional financing may not be available on acceptable terms. The filing also identifies shareholder activism as a potential source of disruption.
- The company had up to $50 million available under a 2021 at-the-market agreement and a purchase agreement allowing up to $20 million of stock sales, subject to limitations; no material drawdowns under these arrangements were reported as of the filing. Additional equity financing could dilute shareholders.
- No legal proceedings were reported. Disclosure controls and procedures were assessed as effective as of September 30, 2021.
Important facts for investors to verify
- Whether cash burn, planned clinical spending, and trial timing remain consistent with management’s stated runway into 2024.
- Enrollment, safety, dose escalation, and follow-up results for Annamycin trials; assess the small and preliminary nature of reported response data.
- Progress and funding status for the WP1122 UK trial and planned U.S. IND, and the continuation or replacement of WP1066 studies.
- Current warrant-liability valuation and its noncash effect on reported net income or loss.
- Any use of the ATM or Lincoln Park facilities, further share issuance, and resulting dilution; verify current share count.
- Whether manufacturing capacity, supply-chain conditions, COVID-19 effects, licensing terms, or external grant support change materially.